PTAB concluded that Petitioner has demonstrated that the preponderance of the evidence of record supports that it would have been obvious to the ordinary artisan at the time of invention to combine Gerberwith O’Donnellor Barrie and/or Sartor, with a reasonable expectation of success. The secondary considerations of nonobviousness raised by Patent Owner are neutral or not in favor of the patentability of the challenged claims, and do not outweigh the other Graham factors in obviousness analysis.

US 8,822,438 (expiring on Aug 24, 2027) claims a method for the treatment of a prostate cancer with abiraterone and prednisone.